Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice - Wikidata - wikimedia - TriplyDB

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

http://www.wikidata.org/entity/Q36383418

about

Molecular biology of lung cancer Afatinib in Non-Small Cell Lung Cancer Profile of farletuzumab and its potential in the treatment of solid tumors Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma Farletuzumab in lung cancer Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Review of the current targeted therapies for non-small-cell lung cancer Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.Emerging therapeutic agents for lung cancer Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health Characteristics of lung cancers harboring NRAS mutations Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials Protein signature of lung cancer tissues Functionalizing genomic data for personalization of medicine.Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.What are we learning from the cancer genome?Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer Current concepts on the molecular pathology of non-small cell lung carcinoma.Tumour heterogeneity in the clinic.HeurAA: accurate and fast detection of genetic variations with a novel heuristic amplicon aligner program for next generation sequencing.The evolving genomic classification of lung cancer.Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.Activated RET and ROS: two new driver mutations in lung adenocarcinoma.Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.

P2860

Q24606677-D81A4E00-6379-43CF-ABD6-E1CB241026F5 Q26749005-299C7D3B-4A0B-4A7C-A254-A9E232FAC000 Q26750431-11D708CD-33CB-477A-8FD2-B6BB90115787 Q26785713-51D5AEEC-16FC-498E-B256-A34AE34208B9 Q26826437-BC08FC5E-D7A5-4120-8DDB-16CE289622AF Q26995506-9B6E80F2-1754-45F4-8363-5F1BCD8900E5 Q26997008-BF43163F-9D7D-4F47-9EA8-D8F03590A6E0 Q27014117-17358E9C-564F-495F-9891-8FCD8CF05A7D Q27015079-ED21033C-BB1E-44F5-B519-9B17070ABB4E Q27025970-40063255-8903-4104-ABB6-D0A7887A36A1 Q27853093-D856D181-3D42-4056-80F1-14D7C6C39D5A Q28070165-16DD3173-91F9-451C-B13C-107A121D136B Q28083446-862F9792-6160-4F81-A207-E0A42D0AB6A9 Q28087366-5D521F68-0ED9-4302-BF55-9594054248C3 Q28649612-198C7D4F-5702-4C5B-A2EE-05EFD1DEA6B9 Q28706226-55506E22-224B-42F3-929D-5CDD92A38690 Q28730438-82194731-F2AA-4F5A-9AE0-B2BEDC69A732 Q28730650-063F2AAC-9BB8-47A3-8731-20FB844634C2 Q30586130-A41D2311-6612-44F4-9808-3E2B5AFCF0F3 Q33688612-92E35A22-D3C8-4B5B-84DA-9FEA0C759A15 Q33906921-CA534589-2579-4258-A953-3E37CFCA3A8B Q33947862-DBBD6CCA-ACF7-4205-98BA-DF4E5D852F9B Q34108365-7335D0BC-E7C3-4D74-B783-3DCC09DDEF6D Q34158153-779FEC7E-05DC-4D7E-A3D4-F165B41C85A2 Q34175045-C83C41EF-B3EA-491A-A6A4-D224C0842B95 Q34213994-A52B8187-29CD-440B-957C-260476C60EBD Q34219452-5AC4850F-9442-40E3-9495-58A053D1DF8F Q34259692-3A58F9A8-A779-4844-A257-A41CE69B5793 Q34310062-BD906387-C2D8-4F6C-801B-FA15C51FA81C Q34372080-C96C1220-4D78-433B-936D-6D30E1DE9D39 Q34562884-8C3D0E62-C04B-4FC2-9980-CC69F984430D Q34852043-AACBB5B0-43E5-4577-AE4C-A99A676ED585 Q35007886-9F0D31A2-2212-497F-A514-7A963BDDD873 Q35062862-E397FC11-8F8B-4A2B-BB7C-955423207FE9 Q35113209-CCCA8D0B-9E47-4CF7-B831-FC2AD0799FD5 Q35170413-C65E06D3-B959-4D66-A59B-9F8A9432D6F1 Q35176080-864A6C0E-0557-438B-A159-61A10D7AABD3 Q35206630-11CBC627-AE0B-4E0B-9283-83AD5328C2BC Q35741716-736B93AD-20ED-41CF-82F4-1D32DA04F270 Q35755392-AECFEE61-CF29-4D62-8A11-D959DECF3EA9

P2860

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

http://www.wikidata.org/entity/Q36383418

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Implementing multiplexed genot ...... into routine clinical practice

@ast

Implementing multiplexed genot ...... into routine clinical practice

@en

type

label

Implementing multiplexed genot ...... into routine clinical practice

@ast

Implementing multiplexed genot ...... into routine clinical practice

@en

prefLabel

Implementing multiplexed genot ...... into routine clinical practice

@ast

Implementing multiplexed genot ...... into routine clinical practice

@en

P1433

Q36383418-77140140-BB3B-4F5B-9673-0EBB602B7CFB

P1476

Q36383418-F5062ADD-B2E4-44D0-9BA1-FB201F07AD68

P2093

Q36383418-0B02FA4C-28AA-4E28-B11F-A174BB8572BD

Q36383418-10D1BFEE-8030-4B24-B9C3-E871C32CCE21

Q36383418-12BF41AC-A154-4723-A19A-0EFEB867D58C

Q36383418-1D8329D7-2740-4D51-B7A9-827C60458F98

Q36383418-2C4E6962-9B9D-4B2B-820D-F527E963783C

Q36383418-2D59AF0D-8CA1-417F-82B5-A51B2C366F8B

Q36383418-36DC12CA-E9C2-44CD-9EAD-95378607B25A

Q36383418-3D70D925-4ED8-4CD6-9AB2-A5B7863860BD

Q36383418-43C4A8E9-6F14-4B38-8462-B13A0C76F57B

Q36383418-55428C77-7455-41C0-A4E7-F5CEEC72812C

P2860

Q36383418-05ADA3DF-940F-4AB1-BA70-E8A32474AC46

Q36383418-07F03967-D058-4A80-B9EB-92C1C60BA602

Q36383418-0A6D6231-7464-4E4B-9A9B-57C6293EDF95

Q36383418-0EE4143C-3167-4B01-ADBC-3AE95BF11057

Q36383418-1259CBC4-207F-45CC-AF81-955367DEC142

Q36383418-15D2A772-4EEC-4C64-8E3E-399917B3E23E

Q36383418-256B079B-F931-44DC-A6B7-797ECFAA008A

Q36383418-2684ECED-D393-4285-940E-3F2A7E31D41A

Q36383418-3627EB35-7923-41AD-97F5-C7B33A93CBDC

Q36383418-381ABEEB-BEEE-4A12-A940-E9902DDA3DB6

P304

Q36383418-23FEAAB2-1391-4E18-A124-3C7E5E48CC72

P31

Q36383418-72EF1741-C8F8-408E-9DDA-A6C8DDA72085

P356

Q36383418-3040CBF9-1233-48E8-8BBC-C0C4A6F4DF6E

P433

Q36383418-AC7A281E-0364-4959-B9F6-79C827F0847D

P478

Q36383418-F7F7C8CB-B29C-45A2-B1B6-5984B706583A

P577

Q36383418-62FFCA18-E7B3-4AF1-86F0-9548EE9B029E

P5875

Q36383418-0863D98B-4BC7-4137-A174-A4670DC336C3

P698

Q36383418-77F0C630-CC90-49BD-925C-633F10BE84B3

P932

Q36383418-58F48AD2-1B43-4DC0-998B-40996D1C790D

P356

P1433

Annals of Oncology

P1476

Implementing multiplexed genot ...... into routine clinical practice

@en

P2093

A J Iafrate

http://www.w3.org/2001/XMLSchema#string

A Muniappan

http://www.w3.org/2001/XMLSchema#string

A Muzikansky

http://www.w3.org/2001/XMLSchema#string

A T Shaw

http://www.w3.org/2001/XMLSchema#string

B A Waltman

http://www.w3.org/2001/XMLSchema#string

C L Channick

http://www.w3.org/2001/XMLSchema#string

C Wright

http://www.w3.org/2001/XMLSchema#string

D Dias-Santagata

http://www.w3.org/2001/XMLSchema#string

D J Mathisen

http://www.w3.org/2001/XMLSchema#string

D M Donahue

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Recurring mutations found by sequencing an acute myeloid leukemia genome

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

Somatic mutations affect key pathways in lung adenocarcinoma

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

P304

2616-2624

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDR489

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51788536

http://www.w3.org/2001/XMLSchema#string

P698

22071650

http://www.w3.org/2001/XMLSchema#string

P932

3493130

http://www.w3.org/2001/XMLSchema#string